Diurnal blood pressure pattern in patients with primary aldosteronism

• Published in: Journal of endocrinological investigation Vol. 29; no. 1; pp. 26 - 31
• Main Authors: Zacharieva, S, Orbetzova, M, Elenkova, A, Stoynev, A, Yaneva, M, Schigarminova, R, Kalinov, K, Nachev, E
• Format: Journal Article
• Language: English
• Published: Italy 01-01-2006
• Subjects: Adenoma - physiopathology; Adrenal Gland Diseases - physiopathology; Adult; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm - physiology; Female; Humans; Hyperaldosteronism - physiopathology; Hyperaldosteronism - therapy; Hypertension - physiopathology; Male; Middle Aged; Sleep; Spironolactone - therapeutic use; Wakefulness
• ISSN: 0391-4097; 1720-8386
• DOI: 10.1007/BF03349173

The aim of the study was to evaluate diurnal blood pressure (BP) profiles in patients with primary aldosteronism and to compare them to those in subjects with essential hypertension. The effects of specific therapy on the circadian BP profiles have been studied.
Sixty-four patients with primary aldosteronism were included in the study. Thirty of them revealed an aldosterone-producing adenoma (APA) and 34 had idiopathic hyperaldosteronism (IHA) due to bilateral adrenal hyperplasia.
We did not find any significant differences in ambulatory BP monitoring (ABPM) between patients with APA and IHA. However, the circadian BP variation in the patients with primary hyperaldosteronism due to APA was preserved, while the patients with IHA showed lower nocturnal decline in comparison with patients with essential hypertension. There was a significant decline in office and ambulatory BP levels after treatment in the patients with both APA and IHA. The awake-sleep BP difference in patients with APA remained unchanged after surgical treatment, while in patients with IHA the night-time systolic and diastolic BP decline was significantly higher after spironolactone treatment.
Primary hyperaldosteronism due to APA was associated with normal circadian BP variability and the surgical treatment led to highly significant decline in all BP parameters but had no influence on the extent of nocturnal BP variation. Spironolactone therapy restored normal nocturnal BP decline in patients with IHA. Reduction of night-time BP decline in patients with IHA is more likely to be related to the duration of the disease rather than to the aldosterone levels.